| 主权项 |
1. A method of inhibiting MCP-1 in a subject in need thereof comprising:
administering to the subject a composition comprising an antibody or an antigen binding fragment that selectively binds to a pyroglutamate-carrying amino-terminus of MCP-1 N1pE, wherein
the antibody or antigen binding fragment has substantially no cross-reactivity with an epitope other than pyroglutamate-carrying amino terminus of MCP-1 N1pE; andthe subject has a disease or condition selected from the group consisting of:
a. a neurodegenerative disease;b. a neurodegenerative disease selected from the group consisting of mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, Familial Danish Dementia, and multiple sclerosis;c. chronic or acute inflammation;d. chronic or acute inflammation selected from the group consisting of rheumatoid arthritis, atherosclerosis, restenosis, and pancreatitis;e. fibrosis;f. fibrosis selected from the group consisting of lung fibrosis, liver fibrosis, and renal fibrosis;g. cancer;h. cancer selected from the group consisting of hemangioendothelioma proliferation and gastric carcinoma;i. a metabolic disease;j. a metabolic disease selected from the group consisting of hypertension; andk. an inflammatory disease selected from the group consisting of neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, and tuberous sclerosis. |
